↓ Skip to main content

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression

Overview of attention for article published in Revista Brasileira de Psiquiatria, October 2014
Altmetric Badge

Mentioned by

twitter
5 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
120 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression
Published in
Revista Brasileira de Psiquiatria, October 2014
DOI 10.1590/1516-4446-2013-1341
Pubmed ID
Authors

Olivia M. Dean, Alyna Turner, Gin S. Malhi, Chee Ng, Sue M. Cotton, Seetal Dodd, Jerome Sarris, Yuval Samuni, Michelle Tanious, Nathan Dowling, Astrid Waterdrinker, Deidre Smith, Michael Berk

Abstract

Objective: Bipolar disorder places a significant burden on individuals, caregivers and family, and the broader community. Current treatments are believed to be more effective against manic symptoms, leaving a shortfall in recovery during the depressive phase of the illness. The current study draws on recent evidence suggesting that, in addition to increased oxidative load, alterations in mitochondrial function occur in bipolar disorder. Methods: This 16-week study aims to explore the potential benefits of N-acetylcysteine (NAC) alone or in combination (CT) with selected nutraceuticals believed to enhance mitochondrial function. The study includes adults diagnosed with bipolar disorder currently experiencing an episode of depression. Participants are asked to take NAC, CT, or placebo in addition to any usual treatments. A post-discontinuation visit is conducted 4 weeks following the treatment phase. Results: The primary outcome of the study will be mean change on the Montgomery-Asberg Depression Rating Scale. Secondary outcomes include functioning, substance use, mania ratings, and quality of life. Blood samples will be collected at baseline and week 16 to explore biochemical alterations following treatment. Conclusion: This study may provide a novel adjunctive treatment for bipolar depression. Analysis of biological samples may assist in understanding the therapeutic benefits and the underlying etiology of bipolar depression. Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12612000830897.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 120 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 <1%
Unknown 119 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 21 18%
Student > Master 20 17%
Researcher 16 13%
Student > Ph. D. Student 11 9%
Student > Doctoral Student 9 8%
Other 22 18%
Unknown 21 18%
Readers by discipline Count As %
Medicine and Dentistry 39 33%
Psychology 15 13%
Nursing and Health Professions 11 9%
Neuroscience 10 8%
Agricultural and Biological Sciences 5 4%
Other 14 12%
Unknown 26 22%